FP7 logo euThe ESNATS project has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement n° HEALTH-F5-2008-201619

Embryonic Stem cell-based Novel Alternative Testing Strategies

Partners: Cell Cure Neurosciences Ltd. (CELL CURE)

Cell Cure Neurosciences Ltd.CELL CURE has extensive experience in culturing and manipulating hESC and developing neural cells from them. In addition, it has established a number of different approaches to characterising the differentiation process and the resulting cell populations as they develop in vitro. There is a particular focus in the company on developing hESC populations enriched for midbrain dopaminergic neurons. As part of the Consortium, CELL CURE offers to use hESC as a platform for CNS toxicity screening (both developmental and acute/subacute) based on existing tools and established capabilities for generation of multipotent neural precursors and midbrain dopaminergic neurons and for their characterisation. Generation of protocols for additional read-outs that could contribute to a neurotoxicity signature will be pursued in coordination with other Consortium members. CELL CURE's activities, together with those of other Consortium members, will allow cross-species (human and mouse) and cross-platform (ESC and «organotypic-like») comparisons of ability to "predict" CNS toxicity as compared to traditional whole animal testing strategies.

Key staff involved in the project

Benjamin Reubinoff, Chief Scientific Officer
In his capacity as CSO of CELL CURE, Prof. Reubinoff directs all the scientific activities of the Company. In addition, he serves as Director of the Human Embryonic Stem Cell Research Center at Hadassah Medical Center and as Associate Professor in Obstetrics and Gynecology. Prof. Reubinoff holds an MD degree from the Hebrew University - Hadassah Medical School, and a PhD from Monash University, Australia. He was at the forefront of the establishment of human embryonic stem cell lines and in manipulating their somatic differentiation in vitro. Prof. Reubinoff's present focus, in which he and his group are among the leaders in the field, is on development of neural precursors and more differentiated neural cells for transplantation therapy.

embryonic stem cells.

Further information: Ofer at cellcure.co.il
POB 12247 Jerusalem 91121 Israel
972-2-641-7467

Top ^